Seattle-based startup RevealDx, formerly known as Mindshare Medical, recently secured $4.25 million in funding to continue developing its software that aims to improve the diagnosis of lung cancer. The company uses machine learning techniques to assess the probability that lung nodules found on chest CT scans are cancerous, which accelerates diagnosis and reduces false positives. RevealDx was acquired by Precision Medical Ventures in 2021, with Mindshare founder Michael Calhoun serving as the company’s CTO.
CEO Chris Wood, who previously founded Clario Medical Imaging and was CTO at Intelerad Medical Systems, has revealed that RevealDx currently has four customers in Europe and is in the process of obtaining FDA approval in the U.S. However, he declined to disclose specific details about investors or other internal metrics. The company’s website features four studies under its “clinical validation” section, indicating the progress of its product development and validation process.
With its focus on enhancing the accuracy and efficiency of lung cancer diagnosis, RevealDx is positioning itself as a key player in the healthcare technology industry. By leveraging advanced machine learning algorithms to analyze CT scans and identify potential cancerous nodules, the company aims to provide healthcare professionals with a powerful tool for early detection and treatment of lung cancer. This innovative approach has the potential to revolutionize the way lung cancer is diagnosed and managed in clinical settings.
Wood’s experience in the health tech sector, including his prior involvement with Clario Medical Imaging, gives him valuable insights and expertise in bringing innovative medical technologies to market. His leadership at RevealDx reflects a commitment to advancing the field of healthcare through cutting-edge solutions that address critical challenges such as early cancer detection. With FDA approval underway and a growing customer base in Europe, RevealDx is well positioned to make a significant impact on the fight against lung cancer through its AI-powered diagnostic software.
As the company continues to expand its reach and develop its technology, it is likely to attract further interest from investors and healthcare providers seeking innovative solutions for cancer diagnosis. The successful completion of FDA approval in the U.S. will be a key milestone for RevealDx, enabling broader adoption of its software within the American healthcare system. By combining scientific rigor with practical applications, the company is at the forefront of a new wave of healthcare innovation that promises to improve patient outcomes and reduce the burden of disease.
Overall, RevealDx’s recent funding round and progress in product development underscore its potential to transform the field of cancer diagnostics, particularly in the context of lung cancer. With a strong leadership team, innovative technology, and a growing customer base, the company is poised to make a significant impact on the healthcare industry by providing advanced tools for early cancer detection and treatment. As RevealDx continues to advance its mission, it is likely to become a key player in the fight against cancer and a pioneer in leveraging AI for improved patient care.
